Item 1(a). |
Name of Issuer:
|
Leap Therapeutics, Inc. (the “Issuer”)
Item 1(b). |
Address of Issuer’s Principal Executive
Offices:
|
47 Thorndike Street, Suite B1-1, Cambridge, MA 02141
Item 2(a). |
Names of Persons Filing:
|
The names of the persons filing this report (collectively, the
“Reporting Persons”) are:
Perceptive Advisors LLC (“Perceptive Advisors”)
Joseph Edelman (“Mr. Edelman”)
Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Item 2(b). |
Address of Principal Business Office or, if
None, Residence:
|
The address of the principal business office of each of the
Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d). |
Title of Class of
Securities:
|
Common Stock, par value $0.001 per share (“Common Stock”)
52187K 101
Item 3. |
If this statement is filed pursuant to
§§240.13d-1(b) or 240.13d-2(b) or (c), check
whether the person filing is a:
|
Not applicable.
The information required by this item with respect to each
Reporting Person is set forth in Rows 5 through 9 and 11 of the
cover page to this Schedule 13G. The ownership percentages are
based on 59,657,742 outstanding shares of Common Stock as reported
in the Issuer’s Form 10-Q
filed on November 12, 2020.
Neither Perceptive Advisors nor Mr. Edelman directly holds any
shares of Common Stock. The Master Fund directly holds 8,476,496
shares of Common Stock. Perceptive Advisors serves as the
investment manager to the Master Fund and may be deemed to
beneficially own the securities directly held by the Master Fund.
Mr. Edelman is the managing member of Perceptive Advisors and
may be deemed to beneficially own the securities directly held by
the Master Fund.